9.31
price down icon0.43%   -0.06
 
loading
Precedente Chiudi:
$9.37
Aprire:
$9.33
Volume 24 ore:
96,747
Relative Volume:
0.01
Capitalizzazione di mercato:
$10.93B
Reddito:
$14.33B
Utile/perdita netta:
$-3.79B
Rapporto P/E:
-2.9369
EPS:
-3.17
Flusso di cassa netto:
$1.84B
1 W Prestazione:
+0.65%
1M Prestazione:
+4.25%
6M Prestazione:
-16.70%
1 anno Prestazione:
-20.26%
Intervallo 1D:
Value
$9.30
$9.36
Intervallo di 1 settimana:
Value
$8.835
$9.41
Portata 52W:
Value
$6.85
$13.55

Viatris Inc Stock (VTRS) Company Profile

Name
Nome
Viatris Inc
Name
Telefono
(724) 514-1465
Name
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Name
Dipendente
32,000
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
VTRS's Discussions on Twitter

Confronta VTRS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
VTRS
Viatris Inc
9.31 10.84B 14.33B -3.79B 1.84B -3.17
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
153.32 67.31B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.73 45.95B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.92 43.35B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.51 18.68B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
305.50 13.44B 2.99B 1.21B 1.13B 25.06

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-06 Iniziato Goldman Neutral
2024-07-19 Ripresa Jefferies Buy
2023-10-23 Downgrade BofA Securities Neutral → Underperform
2023-06-23 Downgrade Barclays Equal Weight → Underweight
2023-04-24 Downgrade Barclays Overweight → Equal Weight
2023-02-17 Downgrade BMO Capital Markets Outperform → Market Perform
2023-01-27 Aggiornamento Jefferies Hold → Buy
2022-11-10 Aggiornamento UBS Sell → Neutral
2022-11-08 Aggiornamento Piper Sandler Underweight → Neutral
2022-10-21 Ripresa Jefferies Hold
2022-06-14 Iniziato UBS Sell
2022-05-10 Downgrade Piper Sandler Neutral → Underweight
2022-03-01 Downgrade BofA Securities Buy → Neutral
2022-03-01 Downgrade Raymond James Outperform → Mkt Perform
2021-06-15 Iniziato Citigroup Neutral
2021-04-07 Ripresa RBC Capital Mkts Outperform
2021-03-08 Downgrade Goldman Buy → Neutral
2021-03-02 Downgrade JP Morgan Overweight → Neutral
2021-02-26 Downgrade Wolfe Research Outperform → Peer Perform
2021-01-05 Iniziato Argus Hold
2020-12-14 Iniziato Bernstein Mkt Perform
Mostra tutto

Viatris Inc Borsa (VTRS) Ultime notizie

pulisher
Jul 23, 2025

What analysts say about Viatris Inc. stockExponential wealth increase - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Viatris’ Wegovy Copy Sheds One Novo Patent in Delaware Lawsuit - Bloomberg Law News

Jul 23, 2025
pulisher
Jul 23, 2025

Covering The Flaws In The Viatris Undervaluation Argument (NASDAQ:VTRS) - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

What to Expect From Viatris' Next Quarterly Earnings Report - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

What To Expect From Viatris' Next Quarterly Earnings Report - Barchart.com

Jul 23, 2025
pulisher
Jul 22, 2025

Is Viatris Inc. a good long term investmentExplosive capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Viatris Inc. stock priceFree Trend-Following Techniques - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

VTRS Down on Late-Stage Study Failure of Eye Disease Drug - MSN

Jul 22, 2025
pulisher
Jul 21, 2025

Agree To Buy Viatris At $5, Earn 3% Using Options - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Viatris’ blepharitis ointment fails Phase III trial - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Viatris Phase III MR-139 trial in blepharitis misses goal - The Pharma Letter

Jul 21, 2025
pulisher
Jul 20, 2025

Viatris Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

Viatris Announces Disappointing Phase 3 Study Results for MR-139 in Blepharitis, But Continues to Focus on Delivering Novel Therapies. - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Viatris' Setback in Blepharitis Trial: A Harbinger or a Hurdle for Ophthalmic Innovation? - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Trend Tracker for (VTRS) - news.stocktradersdaily.com

Jul 19, 2025
pulisher
Jul 19, 2025

Viatris Inc. Stock Forecasts: Trial Miss Pressures Recovery of Core Business - AInvest

Jul 19, 2025
pulisher
Jul 18, 2025

Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target - TradingView

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review - Benzinga

Jul 18, 2025
pulisher
Jul 18, 2025

Why Viatris (VTRS) Stock Is Falling Today - TradingView

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris stock unchanged as Goldman maintains Neutral rating on trial miss - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Shares Dip After Blepharitis Treatment Fails to Hit Main Study Goal - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target - Barron's

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris' Resilience in Ophthalmology: Navigating Setbacks and Strategic Growth - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Why Is Viatris Stock Falling In Pre-market? - Nasdaq

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris stock down on late-stage trial setback (VTRS:NASDAQ) - Seeking Alpha

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris eye ointment fails late-stage study, shares fall - TradingView

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris stock falls after Phase 3 blepharitis study misses endpoint - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris blepharitis treatment fails to meet primary endpoint in trial - Investing.com India

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris eye therapy fails to meet late-stage trial goal - TradingView

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis - PR Newswire

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris (VTRS) Announces Positive Top-line Results from VEGA-3 - MSN

Jul 18, 2025
pulisher
Jul 17, 2025

Viatris (VTRS) Receives a Hold from Goldman Sachs - The Globe and Mail

Jul 17, 2025
pulisher
Jul 16, 2025

Hypopituitarism Treatment Market Expansion Supported - openPR.com

Jul 16, 2025
pulisher
Jul 16, 2025

Viatris: A Contrarian Bet with Minimal Downside Risk - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Viatris: A Contrarian Bet With Virtually No Downside (NASDAQ:VTRS) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 16, 2025

Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT - MSN

Jul 16, 2025
pulisher
Jul 15, 2025

Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

Viatris' Canadian Workplace Excellence Fuels Long-Term Resilience in Pharma's Turbulent Landscape - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Viatris Certified as a Great Place to Work® in Canada - Yahoo Finance

Jul 15, 2025

Viatris Inc Azioni (VTRS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_specialty_generic RDY
$14.74
price up icon 0.96%
$132.60
price down icon 0.35%
$305.50
price up icon 0.42%
$14.96
price down icon 0.06%
$72.83
price down icon 0.66%
Capitalizzazione:     |  Volume (24 ore):